Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 01, 2018

SELL
$29.37 - $49.48 $393,558 - $663,032
-13,400 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$42.06 - $62.4 $69,399 - $102,960
1,650 Added 14.04%
13,400 $609,000
Q1 2018

May 02, 2018

BUY
$50.12 - $67.72 $355,852 - $480,812
7,100 Added 152.69%
11,750 $620,000
Q4 2017

Jan 29, 2018

SELL
$57.69 - $84.58 $1.4 Million - $2.05 Million
-24,270 Reduced 83.92%
4,650 $316,000
Q3 2017

Oct 31, 2017

BUY
$67.17 - $84.81 $1.94 Million - $2.45 Million
28,920
28,920 $2.38 Million

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0

About Clovis Oncology, Inc.


  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Morse Asset Management, Inc Portfolio

Follow Morse Asset Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morse Asset Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Morse Asset Management, Inc with notifications on news.